FYU 981

Drug Profile

FYU 981

Alternative Names: FYU-981

Latest Information Update: 21 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fuji Yakuhin
  • Class Uricosurics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperuricaemia

Most Recent Events

  • 27 Dec 2017 Mochida Pharmaceutical in collaboration with Fuji Yakuhin plans a phase III comparative study of FYU 981 with febuxostat for Hyperuricaemia with or without gout in Japan in January 2018 (NCT03372200)
  • 18 Dec 2017 Mochida Pharmaceutical plans a phase I trial in Hyperuricaemia (with or without gout) in Japan (FYU-981-013; NCT03375632)
  • 28 Nov 2017 Mochida Pharmaceutical in collaboration with Fuji Yakuhin plans a phase I drug-drug interaction study of FYU 981 and oxaprozin (In Volunteers) in Japan in November 2017 (NCT03350386)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top